Improvement in glycemic control of type 2 diabetes after successful treatment of hepatitis c virus

Diabetes Care

Volumn 40, Issue 9, 2017, Pages 1173-1180

  Hum, Justine ^a   Jou, Janice H ^a   Green, Pamela K ^b   Berry, Kristin ^b   Lundblad, James ^a   Hettinger, Barbara D ^a   Chang, Michael ^a   Ioannou, George N ^b,c  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ANTIVIRUS AGENT; GLYCOSYLATED HEMOGLOBIN; INSULIN; RIBAVIRIN;

AGED; BLOOD; BODY MASS; CHRONIC HEPATITIS C; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; SUSTAINED VIROLOGIC RESPONSE;

AGED; ANTIVIRAL AGENTS; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; FEMALE; GLYCATED HEMOGLOBIN A; HEPATITIS C, CHRONIC; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; RIBAVIRIN; SUSTAINED VIROLOGIC RESPONSE;

EID: 85028087674     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc17-0485     Document Type: Article

References (51)

1. Lecube A, Hernández C, Genescà J, Simó R. Glucose abnormalities in patients with hepatitis C virus infection: epidemiology and pathogenesis. Diabetes Care 2006;29:1140-1149
2. Mason AL, Lau JY, HoangN, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999;29:328-333
3. Antonelli A, Ferrari SM, Giuggioli D, et al. Hepatitis C virus infection and type 1 and type 2 diabetesmellitus. World J Diabetes 2014;5:586-600
4. Caronia S, Taylor K, Pagliaro L, et al. Further evidence for an association between non-insulindependent diabetesmellitus and chronic hepatitis C virus infection. Hepatology 1999;30:1059-1063
5. Everhart J. A confluence of epidemics: does hepatitis C cause type 2 diabetes? Hepatology 2001;33:762-763
6. Allison ME, Wreghitt T, Palmer CR, Alexander GJ. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol 1994;21:1135-1139
7. Mehta SH, Brancati FL, Strathdee SA, et al. Hepatitis C virus infection and incident type 2 diabetes. Hepatology 2003;38:50-56
8. Copps KD,WhiteMF. Regulation of insulin sensitivity by serine/threonine phosphorylation of insulin receptor substrate proteins IRS1 and IRS2. Diabetologia 2012;55:2565-2582
9. Kawaguchi T, Yoshida T, Harada M, et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling Am J Pathol 2004;165: 1499-1508
10. SheikhMY, Choi J,Qadri I, Friedman JE, Sanyal AJ.Hepatitis C virus infection:molecular pathways to metabolic syndrome. Hepatology 2008;47: 2127-2133
11. Parvaiz F,Manzoor S, Iqbal J, Sarkar-DuttaM, Imran M, Waris G. Hepatitis C virus NS5A promotes insulin resistance through IRS-1 serine phosphorylation and increased gluconeogenesis. World J Gastroenterol 2015;21:12361-12369
12. Bastard JP, Maachi M, Van Nhieu JT, et al. Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin EndocrinolMetab 2002; 87:2084-2089
13. Nelson DR, Lim HL, Marousis CG, et al. Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection. Dig Dis Sci 1997;42:2487-2494
14. Lecube A, Hernández C, Genescà J, Simó R. Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients: a case-control study. Diabetes Care 2006; 29:1096-1101
15. Arase Y, Suzuki F, Suzuki Y, et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 2009;49:739-744
16. Brandman D, Bacchetti P, Ayala CE,Maher JJ, KhaliliM. Impact of insulin resistance on HCV treatment response and impact of HCV treatment on insulin sensitivity using direct measurements of insulin action. Diabetes Care 2012;35:1090-1094
17. Simó R, Lecube A, Genescà J, Esteban JI, Hernández C. Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection. Diabetes Care 2006;29:2462-2466
18. Delgado-BorregoA, Jordan SH, Negre B, et al.; Halt-C Trial Group. Reduction of insulin resistance with effective clearance of hepatitis C infection: results from the HALT-C trial. Clin Gastroenterol Hepatol 2010;8:458-462
19. Kawaguchi T, Ide T, Taniguchi E, et al. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2 Am J Gastroenterol 2007; 102:570-576
20. Ioannou GN, Beste LA, ChangMF, et al. Effectiveness of sofosbuvir, ledipasvir/sofosbuvir, or paritaprevir/ritonavir/ombitasvir and dasabuvir regimens for treatment of patients with hepatitis C in the Veterans Affairs National Health Care System. Gastroenterology 2016;151:457-471.e5
21. Ampuero J, Romero-Gómez M. Pharmacogenetics of ribavirin-induced anemia in hepatitis C. Pharmacogenomics 2016;17:1587-1594
22. Kesson CM, Whitelaw JW, Ireland JT. Druginduced haemolysis and fast haemoglobin A1 in diabetes mellitus. BMJ 1979;2:1037-1038
23. Van Vlierbergh H, Delanghe JR, De Vos M, Leroux-Roel G; BASL Steering Committee. Factors influencing ribavirin-induced hemolysis. J Hepatol 2001;34:911-916
24. Miller DR, SaffordMM, Pogach LM.Who has diabetes? Best estimates of diabetes prevalence in the Department of Veterans Affairs based on computerized patient data. Diabetes Care 2004; 27(Suppl. 2):B10-B21
25. Backus LI, Boothroyd DB, Phillips BR,Mole LA. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 2007; 46:37-47
26. Beste LA, Ioannou GN, LarsonMS, ChapkoM, Dominitz JA. Predictors of early treatment discontinuation among patientswith genotype 1 hepatitis C and implications for viral eradication. Clin Gastroenterol Hepatol 2010;8:972-978
27. Davila JA, Henderson L, Kramer JR, et al. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med 2011;154:85-93
28. Kanwal F, Hoang T, Kramer JR, et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 2011;140:1182-1188.e1.
29. Kramer JR, Kanwal F, Richardson P, Giordano TP, Petersen LA, El-Serag HB. Importance of patient, provider, and facility predictors of hepatitis C virus treatment in veterans: a national study. Am J Gastroenterol 2011;106:483-491
30. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007;46:32-36
31. Zeuzem S, Heathcote EJ, Shiffman ML, et al. Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C. J Hepatol 2003;39:106-111
32. Yoshida EM, Sulkowski MS, Gane EJ, et al. Concordance of sustained virological response 4, 12, and 24weeks post-treatmentwith sofosbuvircontaining regimens for hepatitis C virus. Hepatology 2015;61:41-45
33. World Health Organization. Use of Glycated Haemoglobin (HbA1c) in theDiagnosis ofDiabetes Mellitus: Abbreviated Report of a WHO Consultation. Geneva, Switzerland, World Health Organization, 2011
34. PatkarA, Fegelman E, Kashyap S, et al. Assessing the real world effect of laparoscopic bariatric surgery on the management of obesity-related comorbidities: a retrospective matched cohort study using a US claims database. Diabetes Obes Metab 2017;19:181-188
35. Ford ES, Cowie CC, Li C, Handelsman Y, Bloomgarden ZT. Iron-deficiency anemia, noniron-deficiency anemia and HbA1c among adults in the US. J Diabetes 2011;3:67-73
36. Riggio O, Montagnese F, Fiore P, et al. Iron overload in patients with chronic viral hepatitis: how common is it? Am J Gastroenterol 1997;92: 1298-1301
37. Bell H, Skinningsrud A, Raknerud N, Try K. Serum ferritin and transferrin saturation in patients with chronic alcoholic and non-alcoholic liver diseases. J Intern Med 1994;236:315-322
38. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Hepatology 2001;33:1554
39. Ng V, Saab S. Effects of a sustained virologic response on outcomes of patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2011;9: 923-930
40. Nathan DM, Genuth S, Lachin J, et al.; Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986
41. King P, Peacock I, Donnelly R. The UK Prospective Diabetes Study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol 1999;48:643-648
42. Bassendine MF, Nielsen SU, Bridge SH, et al. Hepatitis C virus and atherosclerosis: a legacy after virologic cure? Clin Res Hepatol Gastroenterol 2017;41:25-30
43. Meissner EG, Lee YJ, Osinusi A, et al. Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients. Hepatology 2015;61:790-801
44. Hashimoto S, Yatsuhashi H, Abiru S, et al. Rapid increase in serum low-density lipoprotein cholesterol concentration during hepatitis C interferonfree treatment. PLoS One 2016;11:e0163644
45. Mirza MS. Obesity, visceral fat, and NAFLD: querying the role of adipokines in the progression of nonalcoholic fatty liver disease. ISRN Gastroenterol 2011;2011:592404.
46. Tang W, Xu Q, Hong T, et al. Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic reviewandmeta-analysis of randomized and non-randomized studies. Diabetes Metab Res Rev 2016;32:200-216
47. Calzadilla-Bertot L, Vilar-Gomez E, Torres-Gonzalez A, et al. Impaired glucose metabolism increases risk of hepatic decompensation and death in patients with compensated hepatitis C virus-related cirrhosis. Dig Liver Dis 2016;48: 283-290
48. Kawaguchi T, Taniguchi E, Morita Y, et al. Association of exogenous insulin or sulphonylurea treatment with an increased incidence of hepatoma in patients with hepatitis C virus infection. Liver Int 2010;30:479-486
49. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care 2010;33:1674-1685
50. Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. Am J Gastroenterol 2013;108: 881-891; quiz 892
51. Smith MW, Joseph GJ. Pharmacy data in the VA health care system.Med Care Res Rev 2003;60 (Suppl.):92S-123S